Endoscopic Ultrasound

Christoph F. Dietrich(Goethe University Frankfurt), Peter Vilmann(University of Copenhagen), Jan Janßen, Felix Herth(Heidelberg University), Eike Burmester, Michael Hocke, Ralf Eberhardt(Heidelberg University), Holger Neye, Silvia Carrara(IRCCS Humanitas Research Hospital), Mark Krasnik, Dieter Nuernberg, Jens Niehaus, Thomas Leineweber, Thomas Beyer(University of Rostock), Paolo Giorgio Arcidiacono(Vita-Salute San Raffaele University), Carlos Ortiz-Moyano, Barbara Braden(Creighton University), Siegbert Faiss(Sana Klinikum Lichtenberg), Christian Greis, Peter Herbert Kann, Hans Werner Sudholt, Michael Mayr, Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Heinrich D. Becker, Marc Giovannini(Institut Paoli-Calmettes), Stephan Hollerbach(Heidelberg University), Wolfgang Fischbach(Klinikum Aschaffenburg), H Seifert, T Topalidis, H. Allgayer, M. Sailer, H. Frey, Christian Jenssen, Annette Fritscher‐Ravens
Unknown
January 1, 2006
10.1055/b-002-52057
Cited by 4

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
|Journal of Clinical Oncology|2008|784
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738